Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
September 08, 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapyUnprecedented improvement was observed...
Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates
August 06, 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
RESOLVE-1 Phase 3 study of lenabasum for treatment of systemic sclerosis on schedule for topline data this summerPhase 2b study of lenabasum for cystic fibrosis topline results on schedule in Q3...
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
July 08, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Dr. Golumbeski formerly led corporate and business development at Celgene and NovartisAppointment adds unique skill set to Corbus Board ahead of several key data readouts this summer Norwood, MA,...
MATEON AND GMP COMPLETED RESEARCH AND SERVICE AGREEMENT
June 22, 2020 08:00 ET
|
Mateon Therapeutics, Inc.
- Mateon and GMP to proceed to clinical development of OT-101 and Artemisin and other antisense drug candidates against COVID-19 AGOURA HILLS, Calif., June 22, 2020 (GLOBE NEWSWIRE) --...
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
May 27, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data on schedule for summer 2020Systemic sclerosis (SSc) is a rare, serious and life-threatening autoimmune disease affecting ~200,000 people in the U.S., EU and JapanThere are no FDA-approved...
Breathtec Provides Nash Pharmaceuticals’ Plans for Next Year
September 13, 2018 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to provide details on Nash...
Newly Issued U.S. Patent Covers Spotlight Innovation's Spinal Muscular Atrophy Drug Candidates
March 13, 2018 09:00 ET
|
Spotlight Innovation Inc.
URBANDALE, IA, March 13, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that U.S. Patent...